GSK plc

Stocks

GSK

GB00BN7SWP63

Market Closed - London S.E. Other stock markets 09:05:23 15/07/2026 pm IST			5-day change	1st Jan Change
1,916.50 ^GBX	-0.21%		-3.18%	+5.04%

08:03pm	GSK Completes $10.6 Billion Acquisition of Nuvalent	MT
07:30pm	GSK completes USD10.6 billion acquisition of Nuvalent	AN

Transcript : GSK plc Presents at Jefferies Global Healthcare Conference 2026, Jun-03-2026 11

Published on 06/04/2026 at 02:51 am IST

S&P Capital IQ

Add MarketScreener to your sources

Presenter Speech
Michael Leuchten (Analysts)

It's my pleasure to introduce GSK. We've got Hesham, he's the Head of Oncology R&D at GSK. Exciting times just coming out of ASCO. I guess, Hesham, thank

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Add MarketScreener to your sources

Latest news about GSK plc

08:03pm	GSK Completes $10.6 Billion Acquisition of Nuvalent	MT
07:30pm	GSK completes USD10.6 billion acquisition of Nuvalent	AN
07:00pm	GSK Closes $10.6 Billion Purchase of Nuvalent	MT
14/07	Where would AI lead Pharma in the long run?
13/07	European Equities Mixed in Monday Trading; Eni to Fuel BMW Corporate Fleets With Renewable Diesel	MT
13/07	UK's FTSE 100 Flat as US-Iran Tension Resurfaces	MT
13/07	GSK : UBS remains Neutral	ZD
13/07	GSK Plc Announces Positive Interim Results From AZUR-1 Phase II Trial Of Jemperli In dMMR/MSI-H Locally Advanced Rectal Cancer	CI
13/07	GSK Says Jemperli Poised to Transform Rectal Cancer Care After Positive Interim Trial Results	MT
13/07	GSK Says Mid-Stage Trial of Jemperli Met Main Goal in Rectal Cancer	MT
13/07	GSK posts encouraging data for bowel cancer treatment Jemperli	AN
13/07	Oil gains lift BP as Iran tensions weigh	AN
13/07	GSK's Jemperli meets main goal in mid-stage rectal cancer trial	RE
13/07	GSK hails cancer trial success; Plus500 backs outlook	AN
13/07	GSK Reports Positive Interim Data for Jemperli in Mid-stage Rectal Cancer Trial	MT